Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709876 | 0.90 | LMNA (0.42) | LMNAUSP2HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL10455405 | 0.85 | LMNA (0.40) | LMNAUSP2HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL13136677 | 0.84 | LMNA (0.52) | LMNA | |
| SCHEMBL708587 | 0.84 | ALDH1A1 (0.42) | LMNAUSP2HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL709354 | 0.81 | LMNA (0.39) | LMNAUSP2HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL10454668 | 0.81 | LMNA (0.52) | LMNAUSP2HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL23817039 | 0.80 | LMNA (0.42) | LMNAUSP2HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL8906827 | 0.80 | ALDH1A1 (0.38) | LMNAUSP2HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL13360114 | 0.79 | LMNA (0.46) | LMNA | |
| SCHEMBL13246460 | 0.78 | LMNA (0.43) | LMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203189-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-07-18 | — | — | EP | disclosed |
| US-8124806-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-02-28 | — | — | US | disclosed |
| US-8124806-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-02-28 | — | — | US | disclosed |
| US-8124806-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-02-28 | — | — | US | disclosed |
| EP-1989179-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-01-26 | — | — | EP | disclosed |
| EP-1989179-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-01-26 | — | — | EP | disclosed |
| US-20100221191-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
| US-20100221191-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
| WO-2009047315-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-04-16 | — | — | WO | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
| US-20080260651-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2008-10-23 | — | — | US | disclosed |
| US-20080260651-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053142-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | LMNA 2151/4885USP2 3731/4885HPGD 3025/4885 |
| US-20100221191-A1 | CONTRAST AGENTS | C5, C1S, C1R | LMNA 1527/4885USP2 3892/4885HPGD 2968/4885 |
| US-20080260651-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | LMNA 2138/4885USP2 3587/4885HPGD 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.